Filing Details
- Accession Number:
- 0001209191-20-027170
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-05-05 16:52:02
- Reporting Period:
- 2020-05-01
- Accepted Time:
- 2020-05-05 16:52:02
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1770787 | 10X Genomics Inc. | TXG | Laboratory Analytical Instruments (3826) | 455614458 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1786391 | J. Benjamin Hindson | C/O 10X Genomics, Inc. 6230 Stoneridge Mall Road Pleasanton CA 94588 | See Remarks | Yes | Yes | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Acquisiton | 2020-05-01 | 33,750 | $0.88 | 101,250 | No | 4 | M | Direct | |
| Class A Common Stock | Disposition | 2020-05-01 | 17,120 | $76.62 | 84,130 | No | 4 | S | Direct | |
| Class A Common Stock | Disposition | 2020-05-01 | 7,394 | $77.53 | 76,736 | No | 4 | S | Direct | |
| Class A Common Stock | Disposition | 2020-05-01 | 8,116 | $78.59 | 68,620 | No | 4 | S | Direct | |
| Class A Common Stock | Disposition | 2020-05-01 | 1,120 | $79.20 | 67,500 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Class A Common Stock | Stock Option (right to buy) | Disposition | 2020-05-01 | 33,750 | $0.00 | 33,750 | $0.88 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 281,250 | 2025-10-27 | No | 4 | M | Direct |
Footnotes
- The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
- This transaction was executed in multiple trades at prices ranging from $76.06 to $77.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $77.065 to $78.05. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $78.06 to $79.05. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $79.09 to $79.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- All of the shares subject to the option are fully vested and exercisable as of the date hereof.
Billionaire Hedge Funds
